drugset / Trial / NCT02403310
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
Phase 1
Completed
21 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the safety of combining selinexor with daunorubicin and cytarabine. The maximal tolerated dose (MTD) of selinexor with daunorubicin and cytarabine will also be established.
Timeline
- Start
- 2015-06-18
- Primary completion
- 2016-09-13
- Completion
- 2021-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |
| Background | Cytarabine | Small molecule | 100 mg/m2 | — |
| Background | Daunorubicin | Small molecule | 45 mg/m2 | — |